Table 2. Role of IFN-γ in the GVL Effect... | American Society of Hematology

Table 2.

Role of IFN-γ in the GVL Effect of Allogeneic Spleen Cells in IL-12–Treated Mice

Group (n)	Survival (%)			Tumor at Autopsy (no. with tumor/total evaluated)
	Day 10	Day 35	Day 64
Syn BMT (3)	100	100	100	0/3
Syn BMT, EL4 (5)^*	100	0	0	5/5
Allo BMT (8)	38	13	0	0/7
Allo BMT, IL-12 (7)	100	86	75	0/8
Allo BMT, IL-12, R4-6A2 (8)^†	100	50	12	0/7
Allo BMT, IL-12, EL4 (9)	100	100	56	0/8
Allo BMT, IL-12, R4-6A2, EL4 (9)	100	33	11	4/9

Group (n)	Survival (%)			Tumor at Autopsy (no. with tumor/total evaluated)
	Day 10	Day 35	Day 64
Syn BMT (3)	100	100	100	0/3
Syn BMT, EL4 (5)^*	100	0	0	5/5
Allo BMT (8)	38	13	0	0/7
Allo BMT, IL-12 (7)	100	86	75	0/8
Allo BMT, IL-12, R4-6A2 (8)^†	100	50	12	0/7
Allo BMT, IL-12, EL4 (9)	100	100	56	0/8
Allo BMT, IL-12, R4-6A2, EL4 (9)	100	33	11	4/9

All EL4 recipients were injected with 500 EL4 cells among with BMC and spleen cells.

R4-6A2: neutralizing rat antimouse IFN-γ MoAb, 2.5 mg administered IP on day 1.